What Is the Best GLP-1 Medication for Weight Loss?

If you're researching the best GLP-1 medication for weight loss, you've likely encountered a growing list of options — Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, and more. With so many choices, determining which GLP-1 is best for weight loss depends on several factors, including your health profile, insurance coverage, and treatment goals. This comprehensive comparison breaks down the evidence so you can have an informed conversation with your healthcare provider.

Understanding GLP-1 Medications for Weight Loss

GLP-1 receptor agonists are a class of medications that mimic the glucagon-like peptide-1 hormone. Originally developed for type 2 diabetes, several GLP-1 medications have gained FDA approval specifically for chronic weight management. They work by reducing appetite, slowing gastric emptying, and improving how your body regulates blood sugar and energy.

Not all GLP-1 medications are created equal when it comes to weight loss. Let's compare the leading options head-to-head.

Head-to-Head Comparison of GLP-1 Medications

Wegovy (Semaglutide 2.4 mg)

FDA-approved for: Chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition

Average weight loss in clinical trials: Approximately 15–17% of body weight over 68 weeks (STEP trials)

How it's taken: Weekly subcutaneous injection

Key advantages:

• One of the highest weight loss percentages among GLP-1-only medications
• Extensive clinical trial data (STEP program)
• Also shown to reduce cardiovascular events (SELECT trial)
• FDA-approved specifically for weight loss

Potential drawbacks:

• Supply shortages have affected availability
• Higher cost without insurance (typically $1,300–$1,500/month)
• Gastrointestinal side effects are common during titration

Zepbound (Tirzepatide)

FDA-approved for: Chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition

Average weight loss in clinical trials: Approximately 20–26% of body weight over 72 weeks at the highest dose (SURMOUNT-1 trial)

How it's taken: Weekly subcutaneous injection

Key advantages:

• Highest average weight loss of any currently approved GLP-1 medication
• Dual-action: targets both GLP-1 and GIP receptors
• May have slightly lower nausea rates compared to semaglutide
• Strong clinical evidence base

Potential drawbacks:

• Newer to market, so less long-term safety data than semaglutide
• Premium pricing (typically $1,000–$1,200/month)
• May not be covered by all insurance plans yet

Ozempic (Semaglutide 0.5–2.0 mg)

FDA-approved for: Type 2 diabetes management (not FDA-approved for weight loss, but widely prescribed off-label)

Average weight loss in clinical trials: Approximately 10–14% of body weight, depending on dose

How it's taken: Weekly subcutaneous injection

Key advantages:

• Well-established safety profile with years of data
• May be easier to obtain insurance coverage for diabetic patients
• Same active ingredient as Wegovy at a lower dose
• Widely available through telehealth platforms

Potential drawbacks:

• Lower maximum dose than Wegovy means potentially less weight loss
• Not FDA-approved for weight management
• Off-label prescribing may complicate insurance coverage

Mounjaro (Tirzepatide)

FDA-approved for: Type 2 diabetes management

Average weight loss in clinical trials: Approximately 15–22% of body weight (SURPASS trials)

How it's taken: Weekly subcutaneous injection

Key advantages:

• Same active ingredient as Zepbound
• Dual GLP-1/GIP receptor action
• Strong weight loss results even at diabetes-indicated doses
• May be covered under diabetes benefits for qualifying patients

Potential drawbacks:

• Not FDA-approved for weight loss
• Off-label use may not be covered by insurance
• Similar side effect profile to other GLP-1 medications

Saxenda (Liraglutide 3.0 mg)

FDA-approved for: Chronic weight management

Average weight loss in clinical trials: Approximately 5–8% of body weight

How it's taken: Daily subcutaneous injection

Key advantages:

• Longest track record among weight loss-specific GLP-1s
• FDA-approved for adolescents aged 12+
• May be more affordable than newer options
• Well-understood safety profile

Potential drawbacks:

• Requires daily injections (vs. weekly for newer options)
• Significantly less weight loss compared to semaglutide and tirzepatide
• Being gradually replaced by more effective alternatives

Rybelsus (Oral Semaglutide)

FDA-approved for: Type 2 diabetes management

Average weight loss in clinical trials: Approximately 5–10% of body weight at available doses

How it's taken: Daily oral tablet

Key advantages:

• No injections required
• Convenient oral dosing
• Same active ingredient as Ozempic and Wegovy
• May appeal to needle-averse patients

Potential drawbacks:

• Lower weight loss compared to injectable semaglutide
• Strict dosing requirements (empty stomach, 30-minute wait before eating)
• Not FDA-approved for weight loss
• Currently available doses may be less effective for weight management

What the Clinical Data Shows

Weight Loss Rankings (by average percentage of body weight lost)

Based on available clinical trial data, here's how the GLP-1 medications rank for weight loss effectiveness:

1. Zepbound/Mounjaro (tirzepatide) — Up to 20–26% body weight loss
2. Wegovy (semaglutide 2.4 mg) — Approximately 15–17% body weight loss
3. Ozempic (semaglutide up to 2.0 mg) — Approximately 10–14% body weight loss
4. Saxenda (liraglutide 3.0 mg) — Approximately 5–8% body weight loss
5. Rybelsus (oral semaglutide) — Approximately 5–10% body weight loss

It's important to note that individual results vary significantly. Factors like starting weight, diet, exercise, genetics, and adherence all play a role in outcomes.

Beyond the Scale: Additional Health Benefits

The best GLP-1 for you may not be the one that produces the most weight loss on paper. Consider these additional benefits:

• Cardiovascular protection: Semaglutide (Wegovy) demonstrated a 20% reduction in major cardiovascular events in the SELECT trial. Tirzepatide cardiovascular outcome trials are ongoing.
• Blood sugar control: All GLP-1 medications improve glycemic control, which matters if you have diabetes or prediabetes.
• Blood pressure: Most GLP-1 medications are associated with modest blood pressure reductions.
• Liver health: Emerging evidence suggests benefits for non-alcoholic fatty liver disease (NAFLD/MASH).

How to Choose the Right GLP-1 for You

Consider Your Insurance Coverage

Cost is often the deciding factor. Check whether your plan covers:

• Weight management medications (Wegovy, Zepbound, Saxenda)
• Diabetes medications that may be prescribed off-label (Ozempic, Mounjaro)
• Prior authorization requirements
• Step therapy requirements (trying one medication before another)

Consider Your Health Profile

Your provider will evaluate:

• BMI and weight-related conditions: Determines FDA-approved options
• Diabetes status: May open additional medication options
• Cardiovascular risk: Semaglutide has proven CV benefits
• Thyroid history: GLP-1 medications carry a boxed warning regarding thyroid C-cell tumors
• History of pancreatitis: May affect eligibility

Consider Your Lifestyle Preferences

• Injection frequency: Weekly (semaglutide, tirzepatide) vs. daily (liraglutide)
• Oral vs. injectable: Rybelsus offers a needle-free option
• Side effect tolerance: Some medications may be better tolerated than others

Consider Availability

Supply shortages have affected several GLP-1 medications. As of early 2026, availability varies by region and pharmacy. Your provider can help identify which medications are currently accessible.

Emerging GLP-1 Medications to Watch

The GLP-1 landscape is evolving rapidly. Several next-generation medications are in late-stage clinical trials:

• Orforglipron (Eli Lilly): An oral GLP-1 that may offer weight loss comparable to injectables
• Survodutide: A dual glucagon/GLP-1 agonist showing promising results
• Retatrutide: A triple-agonist (GLP-1/GIP/glucagon) with early data showing up to 24% weight loss
• Amycretin (Novo Nordisk): An oral amylin/GLP-1 combination with early data suggesting up to 13% weight loss in 12 weeks

These medications could expand options significantly in the coming years.

Frequently Asked Questions

Which GLP-1 medication has the fewest side effects?

Side effect profiles are generally similar across GLP-1 medications, with nausea, vomiting, diarrhea, and constipation being the most common. Some evidence suggests tirzepatide (Mounjaro, Zepbound) may cause slightly less nausea than semaglutide, though individual responses vary considerably. Your provider can help identify which medication may be best tolerated based on your health history.

Can I switch GLP-1 medications if the first one doesn't work?

Yes, switching between GLP-1 medications is common and may be recommended if you experience intolerable side effects, inadequate weight loss, or insurance coverage changes. Your provider will guide the transition, which typically involves adjusting doses to find an equivalent starting point on the new medication.

Is Zepbound really better than Wegovy for weight loss?

Clinical trial data suggests that tirzepatide (Zepbound) may produce greater average weight loss than semaglutide (Wegovy) — approximately 20–26% vs. 15–17% of body weight. However, head-to-head trials are limited, and individual results vary. The "best" medication depends on your unique health profile, tolerance, and access.

Do I need to have diabetes to get a GLP-1 prescription?

No. Wegovy, Zepbound, and Saxenda are FDA-approved for weight management in non-diabetic patients who meet BMI criteria. You may qualify with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as hypertension, high cholesterol, or sleep apnea.

How long do I need to take GLP-1 medications?

GLP-1 medications are currently prescribed as long-term treatments for chronic weight management. Research shows that most patients regain a significant portion of lost weight after stopping the medication. Your healthcare provider can help develop a long-term treatment plan that aligns with your goals and health needs.

Taking the Next Step

Choosing the best GLP-1 medication for weight loss is a personal decision that should be made in partnership with a qualified healthcare provider. While clinical data provides helpful guidance, your individual health profile, insurance coverage, and lifestyle preferences all play important roles in determining the right fit.

Ready to explore your options? Take our free eligibility quiz →

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.